西羅珠單抗

維基百科,自由的百科全書
西羅珠單抗
單克隆抗體
種類完整抗體
目標成纖維細胞激活蛋白英語Fibroblast activation protein
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號216669-97-5  ☒N
ChemSpider
  • none
UNII

西羅珠單抗INN:sibrotuzumab)是一種用於治療癌症的人源化單克隆抗體。它與成纖維細胞激活蛋白英語Fibroblast activation protein結合。[1][2]

2003年,它在轉移性結直腸癌的II期臨床試驗中失敗。[3]

參考資料[編輯]

  1. ^ Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clinical Cancer Research. May 2003, 9 (5): 1639–47. PMID 12738716. 
  2. ^ Kloft C, Graefe EU, Tanswell P, Scott AM, Hofheinz R, Amelsberg A, Karlsson MO. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Investigational New Drugs. January 2004, 22 (1): 39–52. PMID 14707493. S2CID 24877721. doi:10.1023/B:DRUG.0000006173.72210.1c. 
  3. ^ Hofheinz RD, al-Batran SE, Hartmann F, Hartung G, Jäger D, Renner C, et al. Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. February 2003, 26 (1): 44–8. PMID 12624517. S2CID 29922209. doi:10.1159/000069863.